Résumé
PURPOSE: To highlight the usefulness of polymerase chain reaction (PCR) for the rapid diagnosis of systemic fungal infections. METHODS: Clinical samples were collected from 50 clinically suspected cases of systemic mycosis and subjected to smear, culture, antifungal sensitivity and PCR (based on 18S rRNA gene). RESULTS: Of the 50 clinical specimens tested by PCR, 39 were found to be positive. PCR gave more positive results than smear and culture examination. Out of the 50 clinical specimens 35 were found to be fungal culture positive. The sensitivity testing results of these fungal isolates showed that there was a good correlation between the in vitro results and the clinical response of the patient to antifungal therapy. Itraconazole exhibited maximum antifungal activity followed by fluconazole, ketoconazole and amphotericin B. CONCLUSIONS: PCR technology provides rapid and accurate diagnosis of fungal infection, however, it must be used with caution to avoid false positives.
Résumé
Eighty eight patients with myelodysplastic syndromes were studied to determine the clinical and pathological features and the prognosis. All the patients had anemia. Neutropenia was seen in 44% and thrombocytopenia in 78% patients. The subtypes included refractory anemia in six, refractory anemia with ringed sideroblasts in three, refractory anemia with excess blasts in 30, refractory anemia with excess blasts in transformation in 32 and chronic myelomonocytic anemia in 17 patients. Forty four patients who received chemotherapy were evaluable for response. Three of the 15 patients treated with hydroxyurea achieved partial remission. Eighteen patients were treated with low dose cytosine arabinoside and complete remission was achieved in five and partial response in six patients. Aggressive chemotherapy was given to 11 patients at the onset of the illness resulting in complete remission in six and partial response in two patients. Nineteen of the 88 patients transformed to acute myeloid leukemia. The crude survival of all the patients ranged from 15 days to 22.5 months. The mortality was due to hemorrhage in 15% and septicemia in 85%. Our data reveals ineffectiveness of the current therapy and emphasizes on the need to develop newer therapeutic approaches.
Sujets)
Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Mâle , Adulte d'âge moyen , Syndromes myélodysplasiques/mortalité , Pronostic , Taux de survie , Résultat thérapeutiqueRésumé
L-asparaginase is a valuable chemotherapeutic agent used in the induction of remission and improvement of long term survival in patients with acute lymphoblastic leukemia. Hyperglycemia is a well known side effect of L-asparaginase. Fourteen patients developed hyperglycemia during induction therapy of acute lymphoblastic leukemia with L-asparaginase, prednisolone, vincristine and daunorubicin. Hyperglycemia was observed after a mean of five doses of L-asparaginase (range 2-10). Seven of fourteen patients had neutropenic related infective episodes. Hyperglycemia resolved in all patients within 12 days (range 4-25) and two patients died of neutropenic septicemia. During reinduction therapy with the same drugs, only one out of ten patients developed hyperglycemia E-coli-L-asparaginase was replaced by Erwinia asparaginase in two patients one of who had recrudescence on further therapy. Close monitoring during L-asparaginase therapy for hyperglycemia will enable prompt recognition and early correction and prevent delay in therapy of acute lymphoblastic leukemia.
Sujets)
Adolescent , Adulte , Asparaginase/effets indésirables , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Hyperglycémie/induit chimiquement , Mâle , Leucémie-lymphome lymphoblastique à précurseurs B et T/traitement médicamenteuxRésumé
The results of 19 children with neuroblastoma under one year of age treated at the Tata Memorial Hospital between 1981-1990 were analysed. Biologically, neuroblastomas in children under the age of 12 months have an entirely different prognosis as compared to older children. There were four children less than six months of age and 15 children between six and 12 months. All patients with stage II (2/2) disease are alive; 3/4 patients with stage IV-S disease are disease free; 3/5 stage III patients are disease free and 2/8 patients with stage IV disease are disease free. The survival of infants with stage II and IV-S is better than for those with stage III and IV disease.
Sujets)
Femelle , Hôpitaux , Humains , Inde , Nourrisson , Nouveau-né , Mâle , Neuroblastome/thérapie , Études rétrospectives , Résultat thérapeutiqueRésumé
Fifty three newly diagnosed patients of de novo acute myelogenous leukaemia (AML) received treatment consisting of remission induction with daunorubicin 60 mg/m2 on day one and continuous infusion of cytosine arabinoside 200 mg/m2/day over 24 h from day one to 7. Thereafter patients in complete remission received consolidation chemotherapy with two identical courses. Complete remission (CR) could be achieved in 40 patients (75.5%). Seven patients (13.2%) died with complications during aplasia phase following remission induction therapy while six patients (11.3%) had resistant disease. Twenty seven patients (67.5%) developed relapse while eight patients (15.1%) continue to remain in complete remission ranging from 51 to 68 months (median 62.5). The projected event free survival and disease free survival at 60 months is 15 per cent (SE + 11.9%) and 21 per cent (+6%) respectively. Evaluation of the prognostic significance of pretherapy characteristics showed that infection at presentation and low number of myeloperoxidase (MPO) containing blasts affected the achievement of complete remission adversely on univariate analysis. Similarly age at diagnosis, of more than 45 yr, total leucocyte count of 50,000/cumm or more and low number of MPO containing blasts affected the remission duration (disease free survival) adversely on univariate analysis. On multivariate analysis, MPO positivity of blast cells, remained the only significant independent characteristic. High MPO positivity affected the remission duration favourably (P < 0.01). Patients with high MPO positivity also achieved CR with one induction cycle in 32 out of 40 instances while only 2 out of 5 patients with low MPO positivity, achieved CR with one chemotherapy cycle (P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
Sujets)
Adolescent , Adulte , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Cytarabine/administration et posologie , Daunorubicine/administration et posologie , Femelle , Cellules souches hématopoïétiques/enzymologie , Humains , Leucémie aigüe myéloïde/traitement médicamenteux , Mâle , Adulte d'âge moyen , Myeloperoxidase/métabolisme , Pronostic , Récidive , Induction de rémissionRésumé
Pure red cell aplasia associated with lymphoproliferative malignancies other than thymoma is an uncommon occurrence. In the present paper we report a rare case of nodular non-Hodgkin's lymphoma with pure red cell aplasia who presented with symptoms related to anemia rather than the lymphoma and responded well to combination chemotherapy.
Sujets)
Adulte , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Femelle , Humains , Lymphome malin non hodgkinien/complications , Érythroblastopénie chronique acquise/complicationsRésumé
Sixteen children with myelodysplastic syndrome as defined by the French-American-British co-operative group are presented. The mean age was 10.5 (2.5 to 16) years, with a male predominance. All patients belonged to the more aggressive subtypes of myelodysplastic syndromes. Seven patients presented with refractory anaemia with excess blasts, six had refractory anemia with excess blasts in transformation, and three had chronic myelomonocytic leukemia. Cytogenetic analysis done in 7 of the 16 patients, revealed karyotype abnormalities involving chromosomes 7, 8 and 17. One patient with Down's syndrome had karyotype of 47, XY, +21 (major clone) and 46, XY (minor clone). Five of these patients evolved to acute leukemia. The mean duration of survival was 5.5 months. Aggressive chemotherapy as a primary line of treatment induced remission in five out of six patients. Predominance of aggressive types of myelodysplastic syndromes in children and their good but short-lived response to aggressive chemotherapy suggests the need for early bone marrow transplantation following chemotherapy.
Sujets)
Adolescent , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Ponction-biopsie à l'aiguille , Moelle osseuse/anatomopathologie , Transformation cellulaire néoplasique/effets des médicaments et des substances chimiques , Enfant , Enfant d'âge préscolaire , Aberrations des chromosomes/génétique , Femelle , Humains , Leucémie aigüe myéloïde/diagnostic , Mâle , Syndromes myélodysplasiques/diagnostic , PronosticRésumé
A computerized system for neonatal case records has been used for the last four years at Kasturba Hospital. The software was developed in-house. The data base can be used to generate discharge summaries, neonatal statistics and epidemiological information. For a single patient, entry of data and printing of the discharge summary takes four to five minutes. Consolidated demographic and epidemiological statistics or selective clinical data for clinical research is easily retrievable. The system is efficient, accurate and easy to operate.
Sujets)
Humains , Nouveau-né , Systèmes informatisés de dossiers médicaux , NéonatologieRésumé
Twenty-five patients with acute nonlymphoblastic leukemia undergoing 41 cycles of chemotherapy with daunorubicin/cytosine arabinoside (ara-C) or with etoposide/ara-C received metoclopramide (MCP; 0.5 mg/kg 6 hourly i.v.) or MCP (same dose) plus oral lorazepam (1 mg/d) during and 24 hours following the chemotherapy as antiemetic medication. Control of vomiting was achieved is 55% (complete 5%, partial 50%) of the patients receiving MCP alone and in 100 percent (complete 76.1%; partial 23.8%) of those receiving MCP plus lorazepam (p less than 0.001). Eighteen of the 21 patients (85.7%) receiving MCP plus lorazepam opted for the same antiemetic regimen as compared to six of the 20 (30%) receiving MCP alone (p less than 0.01). One patient in each group developed mild sedation during the treatment. It is concluded that oral lorazepam is an effective and safe adjuvant to MCP for the control of vomiting during cancer chemotherapy.
Sujets)
Adjuvants pharmaceutiques/administration et posologie , Administration par voie orale , Adolescent , Adulte , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Association médicamenteuse , Femelle , Humains , Leucémie aigüe myéloïde/traitement médicamenteux , Lorazépam/administration et posologie , Mâle , Métoclopramide/administration et posologie , Adulte d'âge moyen , Vomissement/induit chimiquementRésumé
Estimation of proteinuria in children is cumbersome when a 24 h urine collection is needed. In the presence of a stable glomerular filtration rate, the ratio of urinary protein and creatinine should reflect the protein excretion. One hundred samples of urine (24 h and random samples) were collected from 50 children with nephrotic syndrome, 25 with nephrotic syndrome in remission and 25 normal children. The 24 h urine total protein and random urine protein-creatinine ratio were assessed on these samples. Linear regression analysis of the results showed excellent correlation between the values (r = 0.81, p less than 0.001). A random urine protein-creatinine ratio of greater than 3.5 correlated with massive proteinuria, while a ratio less than 0.2 was suggestive of physiological values. The sensitivity, specificity, positive and negative predictive values of the protein-creatinine ratio in massive proteinuria were very high. We conclude that the random urine protein-creatinine ratio can be used reliably to assess the degree of proteinuria in children.
Sujets)
Enfant , Rythme circadien/physiologie , Créatinine/urine , Faux négatifs , Humains , Syndrome néphrotique/diagnostic , Protéinurie/diagnostic , Valeurs de référence , Analyse de régression , Manipulation d'échantillons/méthodesRésumé
A preliminary experience in the use of central venous catheters, including Hickman (15), subclavian jugular (Desseret) (50) and Secalon Hydrocath (3), in cancer chemotherapy is presented. There were no technical complications and no mortality attributable to catheterisation. Infections formed the major complication in Hickman (30%) and subclavian jugular (Desseret) (36%) catheters, while the use of Secalon Hydrocath was event-free. The commonest organism isolated was P aeruginosa (60%), followed by staphylococci (30%). Prolonged venous access was achieved with minimum morbidity. It is concluded that central venous catheters are safe and convenient both for the patient and the treating team, and should be used in all patients undergoing protracted chemotherapy and supportive care.
Sujets)
Adolescent , Adulte , Antinéoplasiques/administration et posologie , Cathétérisme veineux central/effets indésirables , Cathéters à demeure , Enfant , Enfant d'âge préscolaire , Contamination de matériel , Femelle , Humains , Mâle , Adulte d'âge moyen , Tumeurs/traitement médicamenteuxRésumé
Thrombocytopenia is a rare side effect of amphotericin B. Two patients with acute leukaemia in remission who developed severe thrombocytopenia during amphotericin B therapy are reported. Thrombocytopenia recovered after the withdrawal of the drug in one patient and after reducing the dose in the other patient.
Sujets)
Adulte , Amphotéricine B/effets indésirables , Aspergillose/traitement médicamenteux , Bronchopneumonie/traitement médicamenteux , Femelle , Humains , Mycoses pulmonaires/traitement médicamenteux , Mâle , Infections opportunistes/traitement médicamenteux , Thrombopénie/induit chimiquementRésumé
The behavioral pattern of small for gestational age (SGA) infants differs from that of appropriate for gestational age (AGA) infants. Maternal malnutrition and SGA infants being a common problem in our country, we assessed the behavior of 36 full term SGA infants using the Brazelton scale. These infants had an excellent orienting capacity, state control and self quieting. Their motor performance was fair and autonomic regulation showed a good recovery over first 10 days. A comparison of this behavior with full term AGA infants showed a better orientation in SGA infants. Though there was a significant difference in motor, state regulation, and autonomic regulation, by the end of the first month they recovered to the same level as the AGA infants. The pattern of SGA behavior described is at marked variance with most of other reports from abroad.